viewAllergy Therapeutics PLC

Allergy Therapeutics highlights benefits of adjuvant technology in new paper

The study highlighted Allergy’s microcrystalline tyrosine (MCT) was a suitable and flexible alternative to aluminium hydroxide

hay fever
MCT generates a faster response

Hay fever vaccine specialist Allergy Therapeutics PLC (LON:AGY) has published new data highlighting the effectiveness of its technology as an adjuvant compared to existing treatment.

An adjuvant stimulates the body’s immune response to an antigen and helps it react quicker to the threat.

WATCH: 'Pivotal' year ahead for Allergy Therapeutics with key trial readouts

The study highlighted Allergy’s microcrystalline tyrosine (MCT) was a suitable and flexible alternative to aluminium hydroxide in both allergen-specific immunotherapy and infectious disease applications. 

"These findings provide evidence of the effectiveness of MCT as an adjuvant, confirming the mechanism of action underlying its ability to induce a robust and sustained immunological response." said Matthias Kramer, Allergy Therapeutics' International Medical Director and co-author of the paper.

"We believe these data highlight the significance of our differentiated proprietary platform technology in the development of our growing suite of cutting-edge, globally marketed ultra-short course allergy vaccines."   

Studies in a cancer (melanoma) model are underway.

Allergy published the findings of its work online in the Journal of Immunology.

Quick facts: Allergy Therapeutics PLC

Price: 14.5 GBX

Market: AIM
Market Cap: £92.41 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...



Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

2 min read